FSD Pharma Inc. HUGE HUGE 0K ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and …
Company reaffirms full year 2023 outlook Sales leverage, operational improvements and cost initiatives drive significant sequential profitability increase Holley Inc. HLLY, a leading platform serving performance automotive enthusiasts, today announced …
CorEnergy Infrastructure Trust, Inc. CORR CORRPrA))) ("CorEnergy" or the "Company") today announced financial results for the first quarter, ended March 31, 2023. First Quarter 2023 and Recent Highlights Reported Total Revenue of $29.3 …
Strong First Quarter Growth Driven by Performance Across Diverse Business Segments Priority Technology Holdings, Inc. PRTH ("Priority" or the "Company"), the platform for unified commerce that delivers integrated payments and banking …
MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. GUD ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, …
MONTRÉAL, May 11, 2023 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. ("Goldstar" or the "Corporation") GDM has entered into a Purchase and Sale Agreement (the "Agreement") for the acquisition of 8 claims (the "IMV Project…
PGT Innovations, Inc. PGTI, a national leader in premium windows and doors, including impact-resistant products, garage doors, and products designed to unify indoor/outdoor living spaces, today announced financial results for its first quarter for the …
Total revenue was €37.6 mm in Q1 2023, while net gaming revenue1 was €39.5 mm in the period, 57% and 55% above those from Q1 2022, respectively. Mexico revenue was €15.8 mm in Q1 2023, while net gaming revenue was €17.6 mm in the period, 75% above of Q1 …
The Real Brokerage Inc. REAX REAX, the fastest-growing publicly traded real estate brokerage, announced results for its first quarter ended March 31, 2023. "Real continues to deliver industry-leading growth in a challenging market with the largest …
Quarterly net revenues of $13.0 million, increased 4% year-over-year Operating expenses of $58.4 million, declined 4% year-over-year; includes $4.3 million of restructuring expenses Acquisition of Apex Crypto closed on April 1, 2023, bringing ~5.8 million …
NEW YORK and TORONTO and LONDON, May 11, 2023 (GLOBE NEWSWIRE) -- Amynta Group, Brit Ltd ("Brit"), a subsidiary of Fairfax Financial Holdings Limited ("Fairfax") FFH, and Fairfax announce the successful completion of the previously …
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for focal epilepsy Cash and investments of $85.8 million as …
– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting – – Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 …
– Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Company ends first quarter with approximately $185.5 million in cash and investments; Anticipated …
Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting Additional Phase 3 VIITAL™ study results presented at International Societies for Investigative …
Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19 patients Gohibic planned to be available to patients in the U.S. within the next few weeks Phase III …
MISSISSAUGA, Ontario, May 11, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. MBXMBXBF Microbix®, ))), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2023 ended March 31, 2023 (…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023 Cash runway into 2025 supports operations and advancement of pipeline of novel molecular glue degraders to key inflection …
36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN selected for presentation as a late breaking clinical trial at ERA Congress 2023 Plan to initiate a pivotal Phase 3 clinical trial of atacicept in IgAN during the second quarter of …
VANCOUVER, May 11, 2023 (GLOBE NEWSWIRE) -- The newest report from Data Bridge Market Research, "Amino Acid in Dietary Supplements Market" examines growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and …
01 days 09:52:01
